ADALIMUMAB vs ADALIMUMAB-RYVK

I am writing this because I am still in shock and honestly struggling to process what happened. I want to know if anyone else with Crohn’s or IBD has experienced something like this and how you dealt with it. I am a 23 year old woman with a severe course of Crohn’s disease affecting the terminal il

31F, 5'6, 145 lbs, white, occasional smoker Humira (adalimumab - for hidradentitis suppurativa) Lamotrigine (mood) Buspirone (anxiety) Vyvanse (ADHD) Let's start off by saying I'm an idiot - when I started taking Humira for my HS a couple years ago I read every about it. I know I am not supposed t

***Disclaimer: This newsflash is for informational purposes. Always consult with your IBD-specialized dietitian or GI team before making significant dietary changes.*** The therapeutic paradigm for ulcerative colitis has shifted fundamentally between 2024 and 2026, transitioning from a reactive

A Quick catch you up on the Rani pill: They have completed a phase one trial of Octreocide in 2019, they still have Phase 2 phase 3 & FDA Approval before commercialization. and have multiple other drug candidates in the background. Capsule dissolves after being swallowed in the small intestine.

**The Scientific History of Adalimumab** Adalimumab is a powerful anti-inflammatory that acts against cytokines, which are protein messengers between cells, that would otherwise encourage inflammation to occur. Adalimumab targets a specific cytokine, TNF, and so we call adalimumab an anti-TNF dr

#Earnings Abbott Laboratories (ABT) Q3 EPS USD 0.75 vs. Exp. USD 0.75, revenue USD 7.7bln vs. Exp. USD 7.65bln. Narrows FY EPS guidance (to USD 2.87-2.89 from 2.85-2.91), but says despite FX headwinds, it is positioned to achieve upper end of its guidance. (Newswires) Cree (CREE) Q1 Adj. EPS US

Hey everyone! I've been on a deep dive into understanding the immune system, particularly in relation to psoriasis. Consolidating information like this really helps me grasp it better. While there's a wealth of knowledge out there, I've highlighted both natural and conventional methods that I've per

Hi all, have had worsening psoriasis and PsA since 2014 and finally today my dermatologist saw me and has put me forward for Adalimumab! I am so happy to finally get approved for a biologic. Fingers crossed it will be the treatment that finally works for me!

Started Skyrizi on Sunday and things are changing. As the old adage goes "Changeable, Curable" I've had one small area of persistent psoriasis clear completely - I'd given it a friction burn from rubbing through clothes on Saturday. On Monday it was red and sore. Tuesday it had dried. Wednesday it p

I’m 23M with psoriasis. I’ve used methotrexate before, then Apremilast for 6 months (stopped working). Now my doctor wants to put me on Tofacitinib, but also asked me to check with insurance about biologics. Shes recommending Ixekizumab (Taltz), but it’s super expensive (₹3–4.5 lakh first year, then

If you'd all humour me while I vent, I'm very much an emotional wreck atm 😅 I've had Plaque Psoriasis since 2012, started on my forehead and then spread to cover my entire face, big patches on my legs, arms, back torso, scalp, ears... You get the drift. After Ciclosporine in 2019 I took a break wit

I’m a 49M Crohn’s veteran, pretty new to Reddit. I’ve been on Humira for the past 10 years with fantastic results. By far the longest remission period since I was diagnosed in 1986. Last summer I had a skin cancer spot on my ear, a basal cell. Had it removed via Moh’s surgery. Now I have another spo

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Lt

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced t

* In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI * SELARSDI is the second biosimilar to launch in the U.S. under t

February 23, 2024 8:15 PM SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for intercha

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration interchangeable biosimilar to Hum

* Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis * The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection i